Bittoni Alessandro, Andrikou Kalliopi, Lanese Andrea, Santoni Matteo, Pellei Chiara, Faloppi Luca, Del Prete Michela, Giampieri Riccardo, Cascinu Stefano
Recenti Prog Med. 2015 May;106(5):208-16. doi: 10.1701/1868.20404.
Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest solid malignancies, with an extremely poor prognosis, with a 1-year survival rate of approximately 20%. Low survival rates of PDAC mainly derive from late diagnosis, with only a minority of patients amenable to surgery, as well as high rates of relapse and lack of effective treatments for advanced disease stages. As a result, there is an urgent need for the development of new effective therapies. At present, the greatest step towards an improvement of treatment has been made with the introduction of two combination chemotherapy regimens, namely FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin) and gemcitabine/nab-paclitaxel. However, current research is also taking a multidirectional approach aiming at developing new treatment options, such as the use of agents targeting the oncogenic network signaling of KRAS or the extracellular matrix, as well as immune therapies.
胰腺导管腺癌（PDAC）仍然是最致命的实体恶性肿瘤之一，预后极差，1年生存率约为20%。PDAC生存率低主要源于诊断延迟，只有少数患者适合手术，以及复发率高和晚期疾病缺乏有效治疗方法。因此，迫切需要开发新的有效疗法。目前，在改善治疗方面迈出的最大一步是引入了两种联合化疗方案，即FOLFIRINOX（亚叶酸、5-氟尿嘧啶、伊立替康和奥沙利铂）和吉西他滨/纳米白蛋白结合型紫杉醇。然而，目前的研究也在采取多方向方法，旨在开发新的治疗选择，如使用靶向KRAS致癌网络信号或细胞外基质的药物，以及免疫疗法。
